The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | RADAR trial: Isa-VRDc induction and Isa-VRD consolidation in newly diagnosed ultra-high-risk myeloma
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the initial results from a cohort of the UK Myeloma Research Alliance (UKMRA) RADAR trial (ISRCTN46841867), which is evaluating the efficacy of isatuximab, bortezomib, lenalidomide, dexamethasone, and cyclophosphamide (Isa-VRDc) induction and Isa-VRD consolidation in newly diagnosed transplant-eligible patients with double hit ultra-high risk myeloma. Dr Ramasamy highlights that the study demonstrated activity in this high-risk patient population. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
